Business Wire

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease

Jaa

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. The study will be independently conducted, analysed and reported by the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU), which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU). Boehringer Ingelheim and Eli Lilly and Company will provide the funding for the study.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005697/en/

The plan to conduct a dedicated outcomes study in people with chronic kidney disease is based on insights previously obtained from the EMPA-REG OUTCOME® trial. This landmark trial investigated the effect of empagliflozin, when added to the standard of care, on cardiovascular outcomes in people with type 2 diabetes and established cardiovascular disease, compared with placebo.1 Approximately one third of patients in the EMPA-REG OUTCOME® trial also had established chronic kidney disease at baseline. A secondary exploratory endpoint of the study provided promising data relating to the reduction in the relative risk of new onset or worsening kidney disease. EMPA-KIDNEY will help to further understand this data.1,2

“The data from the EMPA-REG OUTCOME® trial indicate that empagliflozin may have the potential to slow progression of kidney disease and to lower cardiovascular risk among people with chronic kidney disease,” said Professor Colin Baigent, Director of the MRC PHRU at the University of Oxford, UK. “Chronic kidney disease is estimated to affect more than 200 million individuals worldwide and many of these patients are at substantial risk of progressing to end-stage kidney disease. In addition, people with chronic kidney disease are at increased risk of premature death from cardiovascular causes. In light of the high medical need in this area, we are excited to be leading the EMPA-KIDNEY study to find out whether empagliflozin could become a new treatment option to improve the lives of people with chronic kidney disease.”

EMPA-KIDNEY will include approximately 5,000 people with established chronic kidney disease, with and without diabetes. The primary outcome of the study is to assess the effect of empagliflozin on time to clinically relevant kidney disease progression or cardiovascular death. The study will be part of the empagliflozin clinical development programme, the largest clinical development programme of an SGLT2 inhibitor.

“We are delighted to partner with such a prestigious academic institution as Oxford University. The scientists at Oxford University have a proven track record in conducting innovative and paradigm changing clinical trials in patients with chronic kidney disease” commented Dr Georg van Husen, Senior Vice President, Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “We share a common interest and commitment to better understand and improve the treatment of chronic kidney disease, and are excited to further explore the potential of empagliflozin in new disease areas.”

“The EMPA-KIDNEY study, which will build on results of the EMPA-REG OUTCOME® trial, will continue to expand our understanding of how empagliflozin can impact the lives of a broad range of people with and without diabetes.” added Jeff Emmick, M.D., Ph.D., vice president, Product Development, Lilly Diabetes. “We look forward to this new partnership, and the opportunity to follow the progress of the EMPA-KIDNEY study.”

About the MRC PHRU at the University of Oxford

The focus of MRC PHRU at the University of Oxford (https://www.mrc-phru.ox.ac.uk/) is to improve treatment and prevention of chronic diseases, particularly cardiovascular disease and metabolic disease (e.g. diabetes mellitus and chronic kidney disease), which collectively account for a large proportion of premature adult deaths and the burden of disability worldwide. MRC PHRU leads innovative clinical trials and meta-analyses to identify important advances that could have a major impact on health. Its worldwide approach, involving the study of large numbers of people, provides reliable information about the causes of disease and the effects of treatments, which can have a major impact on global health.

About EMPA-KIDNEY: The study of heart and kidney protection with empagliflozin

EMPA-KIDNEY is a multinational randomised, double-blind, placebo-controlled clinical trial. It is designed to evaluate the effect of empagliflozin on clinically relevant outcomes: kidney disease progression and cardiovascular mortality risk. The primary outcome is defined as time to a first event of either a cardiovascular death or kidney disease progression, defined as end stage kidney disease (the need for kidney replacement therapy such as, dialysis or kidney transplantation)3, a sustained decline in eGFR to <10mL/min/1.73m2, renal death or a sustained decline of ≥40% in eGFR from randomisation. EMPA-KIDNEY will include people with established chronic kidney disease both with and without diabetes receiving current standard of care.

The study will be conducted in selected countries representing a global footprint and aims to randomise approximately 5,000 participants to receive either empagliflozin 10 mg once daily or placebo, on top of standard of care.

About Chronic Kidney Disease

Chronic kidney disease is defined as a progressive decline of kidney function over time.

About two thirds of chronic kidney disease cases are attributable to metabolic conditions such as diabetes, obesity and hypertension.4,5,6

Notably, chronic kidney disease is associated with increased morbidity and mortality. The majority of deaths among people with chronic kidney disease occur as a result of cardiovascular complications, often before reaching end stage kidney disease.7,8,9 Once end stage kidney disease is reached, affected individuals have to undergo kidney replacement treatments, such as chronic dialysis or kidney transplantation.3 Chronic kidney disease is highly prevalent in various parts of the world, affecting more than 10 percent of the population.10 Since there is currently no approved treatment available to specifically reduce kidney disease progression and cardiovascular death, the overarching unmet medical need for new treatment options in people with chronic kidney disease is evident.

About EMPA-REG OUTCOME ®1,2

EMPA-REG OUTCOME® is a long-term, multinational, randomised, double-blind, placebo-controlled clinical trial of more than 7,000 people from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

Although the EMPA-REG OUTCOME® trial was not designed to assess the potential mechanisms behind the effect of empagliflozin on kidney outcomes, the kidney assessment was part of a pre-specified exploratory analysis plan of secondary endpoints.

The overall safety profile of empagliflozin in the EMPA-REG OUTCOME® trial was consistent with that of previous trials.

About Empagliflozin

Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death reduction data in the label in several countries.11,12,13

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.

Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/EMPA-KIDNEY

Contact information

Dr Petra Kienle
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877
or
Grant Smith
Manager, Global Business Communications
Eli Lilly and Company
Email: grant.smith@lilly.com
Phone: +1 (317) 954-9907
or
Andrew Trehearne
Communications at MRC PHRU
Phone: +44 (0) 1865 743960
Mobile: +44 (0) 7979 940972

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EETTiedote

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.

Bidgely EV Solution Detects Charging Patterns for Vehicle-to-Grid Integration25.3.2019 19:36:00 EETTiedote

Bidgely today introduced an Electric Vehicle (EV) Solution for global utilities that applies artificial intelligence and machine learning to customer data for smart vehicle-to-grid (V2G) integration. With Bidgely’s industry-leading EV disaggregation patent serving as the foundation, the new EV Solution identifies territory-wide residential charging patterns and pinpoints homes with EVs for targeted product and service offerings that help utilities enhance customer engagement, manage the grid more effectively and generate new revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005621/en/ The new Bidgely EV Solution identifies territory-wide residential charging patterns and pinpoints homes with EVs for targeted product and service offerings that help utilities enhance customer engagement, manage the grid more effectively and generate new revenue. (Graphic: Business Wire) “Beneficial electrification, and EVs in parti

The International Society for Quality in Health Care Partners with the Patient Safety Movement Foundation to Achieve Zero Preventable Deaths in Hospitals25.3.2019 19:30:00 EETTiedote

The International Society for Quality in Health Care (ISQua) is pleased to announce their support of the Patient Safety Movement Foundation (PSMF) and their mission to eliminate preventable deaths in hospitals, with a signed cooperation agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005265/en/ With this agreement, ISQua and PSMF agree to work together to further their aims to improve quality and safety in healthcare and eliminate preventable patient deaths. The partnership will provide synergy so that our missions can be amplified. ISQua and PSMF will work together to identify common projects in the field of patient safety and promote each other’s activities on an ongoing basis. ISQua and PSMF will hold joint sessions at their respective conferences, at ISQua’s 36th International Conference (20th – 23rd October 2019) in Cape Town, South Africa; and PSMF’s 8th Annual World Patient Safety, Science & Technology

The Results Are In! BOC Group Named a Leader in the Enterprise Architecture Management Suites, Q1 2019 report by Independent Research Firm25.3.2019 16:32:00 EETTiedote

BOC Group, the leading global provider of Enterprise Management Solutions, announced today that it has been recognized as a “Leader” in The Forrester Wave™: Enterprise Architecture Management Suites, Q1 2019 report. Evaluated against 35 rigorous criteria, BOC Group’s EA suite ADOIT received the highest possible scores in 16 of them, including customer satisfaction, innovation agenda criteria and many others! Christoph Moser, ADOIT product manager, comments on this accomplishment by saying: “We see this achievement as an affirmation of our unwavering position as a front-runner in the EA industry and a direct reflection of the strength, depth and breadth we have incorporated across all aspects of our comprehensive, user-centric EA offering and portfolio in the last years.” Moser continues: “For us, this recognition is hard-earned and well deserved. But more importantly, we believe it further proves our strategy, relentless commitment to our customers, and continued mission to enable orga

ResMed Launches Next-generation ReSupply Solution25.3.2019 16:00:00 EETTiedote

ResMed (NYSE: RMD) (ASX: RMD) today launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and improve patient satisfaction. Patients enrolled in an automated resupply program are 50 percent less likely to stop PAP (positive airway pressure) therapy within the first year, according to a 2018 study. ResMed’s program goes one step further, automating enrollment as patients meet compliance requirements and letting patients choose their preferred contact method – text, email or live call. Patients can also order supplies through a web- or mobile-based patient portal. HMEs are able to manage all their patients’ resupply needs from a single comprehensive dashboard so they can quickly identify, prioritize and assign tasks. “The new resupply platform is simple and easy to use – everything you need is at your fingertips,” said Kera Tennyson, a PAP location manager at Advanced Medical Solut

Sigma Systems Named Finalist for 4 Industry Awards25.3.2019 15:00:00 EETTiedote

Sigma Systems, the global leader in catalog-driven software, today announced that it has been named as a finalist for two TM Forum Excellence Awards and as a semi-finalist for two Pipeline Innovation Awards. The TM Forum’s Excellence Awards highlight companies and individuals that demonstrate commitment to the evolution of the industry through digital transformation and the adoption of best practices and standards that TM Forum delivers through its Collaboration Community. Sigma is a finalist in the Service Innovator of the year and Catherine Michel is a finalist for the CTO of the Year – an award that she won in 2018. Nik Willetts, CEO, TM Forum said “Congratulations to the finalists of the TM Forum Excellence Awards 2019. As ever, the quality of the competition this year was incredibly high. With 5G fast approaching and pressure to digitally transform intensifying, it’s great to see these organizations pave the way for change and transformation. We’re excited and proud to work alongs

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme